Join our daily newsletter At The Bell to receive exclusive market insights
- G Medical Innovations (GMV) has seen its Independent Diagnostic Testing Facilities (IDTF) be implemented in four U.S. university hospitals
- Around 2000 patients that require cardiac and remote monitoring technologies have already been referred
- Once a has patient has enrolled, they will begin an individualised monitoring service that can range from 24 hours to 30-days
- It is expected that more U.S. hospitals will implement this platform and G Medical is aiming to expand to other markets outside of the states
- G Medical’s share price is up a steady 14.3 per cent and shares are trading for 6.4 cents each
G Medical Innovations (GMV) has seen its Independent Diagnostic Testing Facilities (IDTF) be implemented in four U.S. university hospitals.
Around 2000 patients that require cardiac and remote monitoring technologies have already been referred and G Medical expects this number to significantly grow.
Once a has patient has enrolled, they will begin an individualised monitoring service that can range from 24 hours to 30-days.
It is expected that more U.S. hospitals will implement this platform and G Medical is aiming to expand to other markets outside of the states.
As more hospitals implement G Medical’s IDTF platform, the company expects its revenue will significantly grow. Last calendar year it received US$5.42 million (around $A7.75 million) in revenue from IDTF alone.
“The implementation of IDTF in these first four U.S. hospitals is an excellent development for GMV and a great endorsement of our cardiac and remote patient monitoring services,” CEO Dr Yacov Geva said.
“Hospital deployments will be a major revenue driver for us and provide an excellent foundation to promote and sell our own monitoring devices to further augment revenue streams,” he added.
G Medical’s share price is up a steady 14.3 per cent and shares are trading for 6.4 cents each at 1:02 pm AEST.
